Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management

Neuroinflammation

Volumn , Issue , 2011, Pages 1-23

  Maghzi, Amir Hadi ^a,b,c   Borazanci, Aimee ^d   McGee, Jeanie ^d   Steven Alexander, J ^e   Gonzalez Toledo, Eduardo ^d   Minagar, Alireza ^d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Isfahan Research Committee of Multiple Sclerosis (IRCOMS)   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Louisiana State University Health Sciences Center at Shreveport   (United States)

^e LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882526134     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384913-7.00001-0     Document Type: Chapter

References (64)

1. Frohman EM, Racke MK, Raine CS Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006 1983, 354:942-955.
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG Multiple sclerosis. N Engl J Med 2000 2007, 343:938-952.
3. Lublin FD, Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 2007, 46:907-911.
4. Kurtzke JF Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993, 6:382-427.
5. Koch-Henriksen N, Sørensen PS The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010 May, 9(5):520-532.
6. Correale J, Ysrraelit MC, Gaitán MI Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009, 132:1146-1160.
7. Maghzi AH, Marta M, Bosca I, Etemadifar M, Dobson R, Maggiore C, et al. Viral pathophysiology of multiple sclerosis: a role for Epstein-Barr virus infection?. Pathophysiology 2010, inpress.
8. Hawkes CH Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult Scler 2007 Jun, 13(5):610-615.
9. Munger KL, Zhang SM, O'Reilly E, Hernán MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62(1):60-65.
10. Zivadinov R, Weinstock-Guttman B, Hashmi K, Abdelrahman N, Stosic M, Dwyer M, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 2009, 73:504-510.
11. Saadatnia M, Etemadifar M, Maghzi AH Multiple sclerosis in Isfahan, Iran. Int Rev Neurobiol 2007, 79:357-375.
12. Maghzi AH, Ghazavi H, Ahsan M, Etemadifar M, Mousavi S, Khorvash F, et al. Increasing female preponderance of multiple sclerosis in Isfahan, Iran: a population-based study. Mult Scler 2010, 16(3):359-361.
13. Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006, 5:932-936.
14. Alonso A, Hernán MA Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008, 71(2):129-135.
15. Dyment DA, Ebers GC, Sadovnick AD Genetics of multiple sclerosis. Lancet Neurol 2004, 3:104-110.
16. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-285.
17. Minagar A, Alexander JS Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003, 9(6):540-549.
18. Bar-Or A The immunology of multiple sclerosis. Semin Neurol 2008, 28:29-45.
19. Bar-Or A Immunology of multiple sclerosis. Neurol Clin 2005, 23:149-175.
20. Lovett-Racke AE, Racke MK Epstein-Barr virus and multiple sclerosis. Arch Neurol 2006, 63:810-811.
21. Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, et al. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med 1997, 75:77-88.
22. Minagar A, Ostanin D, Long AC, Jennings M, Kelley RE, Sasaki M, et al. Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells. Mult Scler 2003, 9:235-238.
23. Davies S, Nicholson T, Laura M, Giovannoni G, Altmann DM Spread of T lymphocyte immune responses to myelin epitopes with duration of multiple sclerosis. J Neuropathol Exp Neurol 2005, 64:371-377.
24. Seder RA, Paul WE Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994, 12:635-673.
25. Trinchieri G, Pflanz S, Kastelein RA The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19:641-644.
26. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human Th17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2000 2007, 13:1173-1175.
27. Alexander JS, Harris MK, Wells SR, Mills G, Chalamidas K, Ganta VC, et al. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler 2010, 16:801-809.
28. Kabat EA, Moore DH, Landow H An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J Clin Invest 1942, 21:571-577.
29. Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol 2003, 171:2725-2733.
30. Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, Antel J Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998, 102(5):1045-1050.
31. Monson NL, Brezinschek HP, Brezinschek RI, Mobley A, Vaughan GK, Frohman EM, et al. Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients. J Neuroimmunol 2005, 158:170-181.
32. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707-717.
33. Poorjavad M, Derakhshandeh F, Etemadifar M, Soleymani B, Minagar A, Maghzi AH Oropharyngeal dysphagia in multiple sclerosis. Mult Scler 2010, 16:362-365.
34. Rao SM, Leo GJ, Bernardin L, Unverzagt F Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991, 41:685-691.
35. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991, 41:692-696.
36. Beatty WW Assessment of cognitive and psychological functions in patients with multiple sclerosis: considerations for databasing. Mult Scler 1999, 5:239-243.
37. Pinkston JB, Kablinger A, Alekseeva N Multiple sclerosis and behavior. Int Rev Neurobiol 2007, 79:323-339.
38. Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicenter retrospective study. Lancet Neurol 1996 2007, 6:677-686.
39. Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, et al. Standardized MR imaging protocol for multiple sclerosis: consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 2006, 27(2):455-456.
40. Paty DW Magnetic resonance in multiple sclerosis. Curr Opin Neurol Neurosurg 1993, 6:202-208.
41. Cotton F, Weiner HL, Jolesz FA, Guttmann CR MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003, 60(4):640-646.
42. Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kingsley D, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992, 42:60-63.
43. Zivadinov R, Leist TP Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging 2005, 15(Suppl. 4):10S-21S.
44. Losseff NA, Wang L, Miller DH, Thompson AJ T1 hypointensity of the spinal cord in multiple sclerosis. J Neurol 2001, 248:517-521.
45. Scott TF, Kassab SL, Pittock SJ Neuromyelitis optica IgG status in acute partial transverse myelitis. Arch Neurol 2006, 63:1398-1400.
46. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
47. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58(6):840-846.
48. Arnason BG, Dayal A, Qu ZX, Jensen MA, Genç K, Reder AT Mechanisms of action of interferon-beta in multiple sclerosis. Springer Semin Immunopathol 1996, 18(1):125-148.
49. Huang YM, Kouwenhoven M, Jin YP, Press R, Huang WX, Link H Dendritic cells derived from patients with multiple sclerosis show high CD1a and low CD86 expression. Mult Scler 2001, 7:95-99.
50. Shapiro S, Galboiz Y, Lahat N, Kinarty A, Miller A The "immunological-synapse" at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta. J Neuroimmunol 2003, 144:116-124.
51. Zang Y, Hong J, Robinson R, Li S, Rivera VM, Zhang JZ Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. J Neuroimmunol 2003, 137:144-153.
52. Ozenci V, Kouwenhoven M, Huang YM, Kivisäkk P, Link H Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin Exp Immunol 2000, 120:147-153.
53. Ozenci V, Kouwenhoven M, Teleshova N, Pashenkov M, Fredrikson S, Link H Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol 2000, 108(1-2):236-243.
54. Prat A, Al-Asmi A, Duquette P, Antel JP Lymphocyte migration and multiple sclerosis: relation with disease course and therapy. Ann Neurol 1999, 46(2):253-256.
55. Yushchenko M, Mäder M, Elitok E, Bitsch A, Dressel A, Tumani H, et al. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. J Neurol 2003, 250:1224-1228.
56. Teitelbaum D, Fridkis-Hareli M, Arnon R, Sela M Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol 1996, 64:209-217.
57. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008, 7:903-914. REGARD study group.
58. Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009, 8:889-897. BEYOND Study Group.
59. Sheremata WA, Minagar A, Alexander JS, Vollmer T The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications. CNS Drugs 2005, 19:909-922.
60. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
61. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910. AFFIRM Investigators.
62. Fidler JM, DeJoy SQ, Gibbons JJ Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986, 137:727-732.
63. Bellosillo B, Piqué M, Barragán M, Castaño E, Villamor N, Colomer D Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 1998, 92:1406-1414.
64. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 2006 1983, 13:227-231.